The CMS has sent letters to physicians and other medical advocates saying that it doesn't plan to reverse a decision to reduce coverage for anemia drugs, including Amgen's Aranesp and Johnson & Johnson's Procrit, which studies suggest are overused and are linked to an increased risk of heart attack and stroke. The CMS said it would give a 30-day window for advocates to produce data that could influence them to change their position.

Related Summaries